The SRHLS initially releases DAC completely, thereby enabling epigenetic reprogramming to correct STING signaling dysfunction in GBM cells, and followed by the gradual release of diABZI (a novel non‐nucleotide‐based ligand that potently activates STING) to induce a robust and sustained immune response. This evidence concerns the gene STING1 and glioblastoma.